Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Small molecule inhibitors targeting the cancers
Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …
Current targeted therapy for metastatic colorectal cancer
T Ohishi, MK Kaneko, Y Yoshida, A Takashima… - International Journal of …, 2023 - mdpi.com
Colorectal cancer (CRC) is the third most common type of cancer and the second leading
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …
Despite recent improvements in treatment and prevention, most of the current therapeutic …
[HTML][HTML] NTRK insights: best practices for pathologists
Since the discovery of an oncogenic tropomyosin-receptor kinase (TRK) fusion protein in the
early 1980s, our understanding of neurotrophic tropomyosin-receptor kinase (NTRK) …
early 1980s, our understanding of neurotrophic tropomyosin-receptor kinase (NTRK) …
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1,
and previously induced deep [objective response rate (ORR) 57.4%] and durable [median …
and previously induced deep [objective response rate (ORR) 57.4%] and durable [median …
Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
Highlights•NTRK gene fusions are oncogenic drivers in a variety of tumor types including
adult and pediatric sarcomas.•TRK inhibitors provide effective treatment options for patients …
adult and pediatric sarcomas.•TRK inhibitors provide effective treatment options for patients …
NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance
F Liu, Y Wei, H Zhang, J Jiang, P Zhang… - Frontiers in oncology, 2022 - frontiersin.org
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusion has been identified as an
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …
oncogenic driver of various solid tumors, and it is rare in non-smalll cell lung cancer …
Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion–positive lung cancers
PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase
(TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers …
(TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers …